RZLT: Rezolute, Inc.
Performance
RZLT -64.03%
Watchlist
Select an item
Summary
RZLT at a glance
RZLT returned -64.03% over the past year and -9.85% a year over five years. Its worst drop in that year was -87.20%, smaller than 0% of stocks on Redstone, and its Sharpe ratio of 0.42 beats 46% of stocks on Redstone. It pays no dividends.
Current Drawdown
-64.63%
Rolling Volatility
73.27%
Actions
Metrics
Risk Indicators
Alpha41.76%
Beta1.15x
Sharpe0.42
Sortino0.53
Omega1.10
Calmar-0.73
Martin0.84
Profile
About RZLT
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $374M
- Listed
- Dec 2011
- Employees
- 58
- Headquarters
- Redwood City, CA
- Website
- rezolutebio.com
Comparisons